Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.56 |
| ▸ | PDE4A | P27815 | 7/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126031 | 0.83 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL7474591 | 0.73 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL27868670 | 0.73 | TDP1 (0.46) | — | |
| SCHEMBL7425565 | 0.72 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL13425085 | 0.72 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7419355 | 0.72 | PDE4D (0.55) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL1553041 | 0.70 | PDE4D (0.85) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2518442 | 0.70 | PDE4D (0.47) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL5794099 | 0.70 | PDE4D (0.65) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1202997 | 0.70 | PDE4D (0.44) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120052122-A1 | Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor | NYCOMED GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20090171096-A1 | Novel process for the preparation of roflumilast | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052122-A1 | Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor | PDE4A, PDE3B, PDE4B | PDE4D 7/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20090171096-A1 | Novel process for the preparation of roflumilast | PLAT, VASP, F2R | PDE4D 27/4885PDE4B 22/4885PDE4A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.